- Home
- VRCA vs AKBA Comparison
VRCA vs AKBA Comparison
Compare VRCA & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRCA
- AKBA
- Stock Information
- Founded
- VRCA 2013
- AKBA 2007
- Country
- VRCA United States
- AKBA United States
- Employees
- VRCA N/A
- AKBA N/A
- Industry
- VRCA Biotechnology: Pharmaceutical Preparations
- AKBA Biotechnology: Pharmaceutical Preparations
- Sector
- VRCA Health Care
- AKBA Health Care
- Exchange
- VRCA Nasdaq
- AKBA Nasdaq
- Market Cap
- VRCA 363.1M
- AKBA 336.2M
- IPO Year
- VRCA 2018
- AKBA 2014
- Fundamental
- Price
- VRCA $0.75
- AKBA $1.91
- Analyst Decision
- VRCA Buy
- AKBA Strong Buy
- Analyst Count
- VRCA 6
- AKBA 2
- Target Price
- VRCA $7.33
- AKBA $5.75
- AVG Volume (30 Days)
- VRCA 646.5K
- AKBA 2.3M
- Earning Date
- VRCA 11-04-2024
- AKBA 11-07-2024
- Dividend Yield
- VRCA N/A
- AKBA N/A
- EPS Growth
- VRCA N/A
- AKBA N/A
- EPS
- VRCA N/A
- AKBA N/A
- Revenue
- VRCA $9,210,000.00
- AKBA $169,879,000.00
- Revenue This Year
- VRCA $291.12
- AKBA N/A
- Revenue Next Year
- VRCA $104.31
- AKBA $3.23
- P/E Ratio
- VRCA N/A
- AKBA N/A
- Revenue Growth
- VRCA 187.45
- AKBA N/A
- 52 Week Low
- VRCA $0.70
- AKBA $0.80
- 52 Week High
- VRCA $11.41
- AKBA $2.48
- Technical
- Relative Strength Index (RSI)
- VRCA 26.09
- AKBA 68.47
- Support Level
- VRCA $1.40
- AKBA $1.30
- Resistance Level
- VRCA $1.74
- AKBA $2.01
- Average True Range (ATR)
- VRCA 0.13
- AKBA 0.12
- MACD
- VRCA -0.06
- AKBA 0.04
- Stochastic Oscillator
- VRCA 0.00
- AKBA 78.52
About VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.